Nina (Das) Shah MD

PubMed

• Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.
  Rahul Banerjee, Amber R Fritz, Othman S Akhtar, Ciara L Freeman, Andrew J Cowan
  Leukemia. 2025-04-01
• 10 citations
  Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.
  Ashraf Badros, Laahn Foster, Larry D Anderson Jr, Chakra P Chaulagain, Erin Pettijohn
  Blood. 2025-01-16
• A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...
  Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
  Future Oncology. 2025-01-01

Journal Articles

• Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs  
  Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature

Abstracts/Posters

• Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and _Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Germline Variation Predicts Treatment Response in Multiple Myeloma
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation
  Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Immunotherapy in Myeloma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autolo... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019